CM
NKTR icon

Caption Management’s Nektar Therapeutics NKTR Stock Holding History

Caption Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,000
Closed -$1.99M – 1894
2025
Q4 		$1.48M Buy
+35,000
New +$1.96M 0.01% 930
2025
Q3 		– Sell
-2,776
Closed -$91.9K – 1922
2025
Q2 		$71.7K Buy
+2,776
New +$31.2K ﹤0.01% 1333
2023
Q3 		– Sell
-11,694
Closed -$101K – 1440
2023
Q2 		$101K Hold
11,694
– – ﹤0.01% 981
2023
Q1 		$123K Buy
+11,694
New +$354K ﹤0.01% 955
2022
Q4 		– Sell
-1,400
Closed -$67K – 1583
2022
Q3 		$67K Sell
1,400
-176
-11% -$10.5K ﹤0.01% 1366
2022
Q2 		$90K Buy
+1,576
New +$99.4K ﹤0.01% 1301
2022
Q1 		– Sell
-161
Closed -$23.8K – 1773
2021
Q4 		$33K Sell
161
-1,572
-91% -$341K ﹤0.01% 1523
2021
Q3 		$467K Buy
1,733
+9
+0.5% +$2.16K 0.01% 1209
2021
Q2 		$444K Buy
+1,724
New +$477K 0.01% 1069
2020
Q4 		– Sell
-1
Closed – – 1173
2020
Q3 		$0 Buy
+1
New +$315 ﹤0.01% 1184
2018
Q3 		– Sell
-467
Closed -$342K – 603
2018
Q2 		$342K Buy
+467
New +$538K 0.03% 340

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caption Management's NKTR Position: Q1 2026 in Review

Caption Management sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 35,000 shares — an estimated $1.99M sold.

Caption Management first reported a position in NKTR in Q2 2018 and held it in 11 quarters. The position peaked at $1.48M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Caption Management reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 35,000 Nektar Therapeutics shares in Q1 2026, an estimated $1.99M.
  • Caption Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 11 quarters.
  • Caption Management's Nektar Therapeutics position peaked at $1.48M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.